Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
ALNY: Leadership change · Other company developments
Filed 8-K for an event or period dated 2026-11-02. Leadership change; Other company developments.
ALNY: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
ALNY: Financial results
Filed 8-K for an event or period dated 2026-10-29. Financial results.
ALNY: third_quarter 2026 lobbying report
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing Issues relating to supply chain tariffs Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
Public: Oct 20, 2026, 5:56 PM EDTOriginal source ↗ALNY: third_quarter 2026 lobbying report
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; U.S. Competitiveness FDA modernization
Public: Oct 20, 2026, 4:07 PM EDTOriginal source ↗ALNY: third_quarter 2026 lobbying report
Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Public: Oct 19, 2026, 5:43 PM EDTOriginal source ↗ALNY: third_quarter 2026 lobbying report
Issues related to the implementation of the Inflation Reduction Act. Home infusion policy. Issues related to MFN drug pricing. Issues relating to supply chain tariffs. Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94). Drug Pricing. FY2026 Labor HHS appropriations. Genetically targeted technologies. Policies related to medical innovation.
Public: Oct 19, 2026, 8:22 AM EDTOriginal source ↗ALNY: third_quarter 2026 lobbying report
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Public: Oct 19, 2026, 7:23 AM EDTOriginal source ↗ALNY: third_quarter 2026 lobbying report
Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development. PDUFA reauthorization, Clinical Trial / IND reform.
Public: Oct 15, 2026, 3:18 PM EDTOriginal source ↗ALNY: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-30. Read the company report for its disclosures.
ALNY: Financial results
Filed 8-K for an event or period dated 2026-07-30. Financial results.
ALNY: second_quarter 2026 lobbying report
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act. Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing Issues relating to supply chain tariffs
Public: Jul 20, 2026, 7:39 PM EDTOriginal source ↗ALNY: second_quarter 2026 lobbying report
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; P.L. 119-21; U.S. Competitiveness
Public: Jul 20, 2026, 6:13 PM EDTOriginal source ↗ALNY: second_quarter 2026 lobbying report
Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Public: Jul 20, 2026, 6:06 PM EDTOriginal source ↗ALNY: second_quarter 2026 lobbying report
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Public: Jul 19, 2026, 3:35 PM EDTOriginal source ↗ALNY: second_quarter 2026 lobbying report
Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.
Public: Jul 16, 2026, 3:06 PM EDTOriginal source ↗ALNY: second_quarter 2026 lobbying report
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Public: Jul 5, 2026, 5:51 AM EDTOriginal source ↗ALNY: Leadership change
Filed 8-K for an event or period dated 2026-05-20. Leadership change.
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- USAspending
- Collection in progress76 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 12:27 PM EST
- Federal Register
- Stale — refresh overdue297 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable31 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:00 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST